SELECTIVE INHIBITORS INTERFERING WITH FIBROBLAST GROWTH FACTOR RECEPTOR AND FRS2 INTERACTION FOR THE PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES
The present technology relates to medicine and includes the use of inhibitors which selectively interfere with the interaction between a fibroblast growth factor receptor and FRS2, and with the interaction with other components of the FRS2 complex. Use of the selective inhibitors described in the present technology leads to a proven increase in anti-tumor efficacy relative to other inhibitors and monoclonal antibodies, a decrease in the toxicity of treatment, and the possibility of achieving complete blockage using a low agent concentration and of conducting long-term treatment. The advantage of the technology includes the development of a novel class of medicinal agents for treating malignant neoplasms and other diseases.
